Enzo Biochem (NYSE:ENZ - Get Free Report) announced its quarterly earnings data on Monday. The medical research company reported ($0.05) EPS for the quarter, Zacks reports. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.
Enzo Biochem Stock Down 1.0 %
Shares of ENZ stock traded down $0.01 during trading on Monday, reaching $1.01. The company had a trading volume of 45,663 shares, compared to its average volume of 100,623. The firm's 50 day simple moving average is $1.09 and its two-hundred day simple moving average is $1.11. Enzo Biochem has a one year low of $0.93 and a one year high of $1.50.
Enzo Biochem Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were paid a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a dividend yield of 39.60%. The ex-dividend date was Friday, November 15th.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on Enzo Biochem in a research note on Monday, December 9th. They issued a "hold" rating for the company.
View Our Latest Analysis on ENZ
About Enzo Biochem
(
Get Free Report)
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enzo Biochem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enzo Biochem wasn't on the list.
While Enzo Biochem currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
